Equity Profile

ADMA

ADMA Biologics, Inc.

Health CareBiotechnology$1.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies....

Key Metrics to Watch

Revenue Growth

Revenue growth is essential for ADMA to demonstrate its ability to scale operations and meet market demand.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help assess how well ADMA is managing its costs relative to its revenue.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADMA Q2-2026 Earnings Preview

Context

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies. Operating in the Health Care sector, ADMA's products are crucial for patients who require immunoglobulin therapies, especially in the context of increasing demand for such treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

In Q1-2026, ADMA reported an EPS of $0.19, which was in line with expectations, but revenue details were not disclosed. The stock reacted negatively, dropping 1.66% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for ADMA's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are keenly awaiting any updates on revenue and market demand.

Bull Case

If ADMA can demonstrate strong revenue growth and continued demand for its therapies, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations for growth or reveals challenges in its market, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for ADMA's immunoglobulin therapies this quarter?

Revenue growth will be a critical indicator of market demand and the company's ability to capitalize on it.

Will ADMA provide any guidance on future earnings or market conditions?

Guidance can significantly influence investor sentiment and expectations for the company's performance moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ADMA to exceed revenue expectations based on increased demand for immunoglobulin therapies.

Supporting Evidence

ADMA has a history of beating EPS estimates 67% of the time, suggesting potential for positive surprises.

The options market is pricing a 27% move, indicating that traders expect significant volatility, which could be driven by positive news.

Key Risk

If revenue growth comes in above 15%, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating ADMA's ability to sustain growth in a competitive landscape, making these metrics crucial.

Bull Confirmed If

Demonstrating revenue growth of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or failure to meet growth expectations would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.9%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a substantial move of nearly 27%, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±26.9% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

61.6%

Calls (13K)P/C Ratio: 1.16Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$318,360.00

21,000 sh

1 insider

Net

$318,360.00

Net selling

Most Active Insiders· 2 open-market trades

President and CEOGrossman Adam S
$318,360.00

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests a potential average one-day move of +0.27%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may react moderately, reflecting uncertainty.

Miss

Should ADMA miss expectations, history suggests an average one-day move of +3.59%, indicating a negative market reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the market demand for immunoglobulin therapies.
2Details on revenue growth and projections for the upcoming quarters.
3Management's commentary on competitive pressures and market positioning.
4Insights into any new product developments or pipeline updates.
5Guidance on future earnings expectations and market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

ADMA Biologics, Inc. is a biotechnology company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies....

Key Metrics to Watch

Revenue Growth

Revenue growth is essential for ADMA to demonstrate its ability to scale operations and meet market demand.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help assess how well ADMA is managing its costs relative to its revenue.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ADMA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+30.88%

Avg Stock Reaction

+0.95%

Last Quarter Recap

In Q1-2026, ADMA reported an EPS of $0.19, which was in line with expectations, but revenue details were not disclosed. The stock reacted negatively, dropping 1.66% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for ADMA's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are keenly awaiting any updates on revenue and market demand.

Bull Case

If ADMA can demonstrate strong revenue growth and continued demand for its therapies, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to meet expectations for growth or reveals challenges in its market, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for ADMA's immunoglobulin therapies this quarter?

Revenue growth will be a critical indicator of market demand and the company's ability to capitalize on it.

Will ADMA provide any guidance on future earnings or market conditions?

Guidance can significantly influence investor sentiment and expectations for the company's performance moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ADMA to exceed revenue expectations based on increased demand for immunoglobulin therapies.

Supporting Evidence

ADMA has a history of beating EPS estimates 67% of the time, suggesting potential for positive surprises.

The options market is pricing a 27% move, indicating that traders expect significant volatility, which could be driven by positive news.

Key Risk

If revenue growth comes in above 15%, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating ADMA's ability to sustain growth in a competitive landscape, making these metrics crucial.

Bull Confirmed If

Demonstrating revenue growth of over 15% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in revenue or failure to meet growth expectations would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.9%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a substantial move of nearly 27%, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±26.9% while ADMA has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

61.6%

Calls (13K)P/C Ratio: 1.16Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$318,360.00

21,000 sh

1 insider

Net

$318,360.00

Net selling

Most Active Insiders· 2 open-market trades

President and CEOGrossman Adam S
$318,360.00

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

97.01%

of float

Insider

1.85%

of float

Holders

474

institutions

Top Holders· as of Dec 2025

Blackrock Inc.
36,333,325 sh · $409.1M
15.64%
2.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ADMA beats expectations, history suggests a potential average one-day move of +0.27%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may react moderately, reflecting uncertainty.

Miss

Should ADMA miss expectations, history suggests an average one-day move of +3.59%, indicating a negative market reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the market demand for immunoglobulin therapies.
2Details on revenue growth and projections for the upcoming quarters.
3Management's commentary on competitive pressures and market positioning.
4Insights into any new product developments or pipeline updates.
5Guidance on future earnings expectations and market conditions.